Advertisement

Knockdown of SF3B1 inhibits cell proliferation, invasion and migration triggering apoptosis in breast cancer via aberrant splicing

  • Ling Zhang
  • Xiaojuan Zhang
  • Haitao Zhang
  • Feng Liu
  • Yanghui Bi
  • Yanyan Zhang
  • Caixia Cheng
  • Jing LiuEmail author
Original Article
  • 83 Downloads

Abstract

Background

Splicing factor 3b subunit 1 (SF3B1) was frequently reported to be significantly mutated in breast cancer. However, the status of SF3B1 expression, its function and molecular consequence in breast cancer remained unreported.

Methods

Immunohistochemistry was used to assess SF3B1expression in 110 breast cancer samples. SF3B1 knock‑down in ZR-75-30 and MDA-MB-231 cells was performed by shRNA transfection. The expression of SF3B1 in cells was detected by quantitative real‑time PCR and western blot. Cell proliferation ability was determined by MTT and colony formation assay. Migration and invasion were determined by transwell assay. Flow cytometry was performed to investigate cell cycle and apoptosis. RNA-sequencing was performed to examine differentially expressed genes and affected alternative splicing events.

Results

SF3B1 is overexpressed in breast cancer tissues compared with normal tissues. Overexpression of SF3B1 is associated with lymph node metastasis. SF3B1 knockdown in MDA-MB-231 and ZR-75-30 breast cancer cells significantly induced the suppression of proliferation, migration, invasion and also enhancement of apoptosis. RNA-sequencing data revealed that 860 genes were significantly up-regulated and 776 genes were significantly down-regulated upon SF3B1 knockdown. Differentially expressed genes enriched in the signaling pathways including Ras signaling pathway; cytokine receptor interaction; tight junction; MAPK signaling pathway, Glycine, serine and threonine metabolism. Alternative splicing analysis revealed that exon skipping (SKIP) and cassette exons (MSKIP) were the most common molecular effect upon SF3B1 knockdown.

Conclusions

Our study suggests that SF3B1 may be an important molecular target for breast cancer treatment and provides a new clue for clinical treatment of breast cancer.

Keywords

SF3B1 Breast cancer MDA-MB-231 ZR-75-30 Splicing 

Notes

Acknowledgements

This work was supported by funding from the National Natural Science Foundation of China (81773150 to LZ.), Natural Science Foundation of Shanxi Province (201801D121339 to JL.), the Program for the Outstanding Innovative Teams of Higher Learning Institutions of Shanxi (OIT 2017 to LZ.), the Doctoral Start up Research Fund of Shanxi Medical University (03201508 to LZ.).

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

Ethical approval

The present study was approved by the Ethics Committee of the Shanxi Medical University (approval No. 2018LL0115) and was conducted in accordance with the ethical standards. All procedures performed in studies involving human participants were in accordance the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration.

Informed consent

Informed consent was obtained from all individual participants included in this study.

References

  1. 1.
    El Marabti E, Younis I. The cancer spliceome: reprograming of alternative splicing in cancer. Front Mol Biosci. 2018;5:80.CrossRefGoogle Scholar
  2. 2.
    Slansky JE, Spellman PT. Alternative splicing in tumors-a path to immunogenicity? N Engl J Med. 2019;380:877–80.CrossRefGoogle Scholar
  3. 3.
    Maguire SL, Leonidou A, Wai P, Marchiò C, Ng CK, Sapino A, et al. SF3B1 mutations constitute a novel therapeutic target in breast cancer. J Pathol. 2015;235:571–80.CrossRefGoogle Scholar
  4. 4.
    Newell F, Kong Y, Wilmott JS, Johansson PA, Ferguson PM, Cui C, et al. Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nat Commun. 2019;10:3163.CrossRefGoogle Scholar
  5. 5.
    Jiménez-Vacas JM, Herrero-Aguayo V, Gómez-Gómez E, León-González AJ, Sáez-Martínez P, Alors-Pérez E, et al. Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer. Transl Res. 2019;S1931–5244:30134–43.Google Scholar
  6. 6.
    Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011;365:2497–506.CrossRefGoogle Scholar
  7. 7.
    Chang YS, Huang HD, Yeh KT, Chang JG. Genetic alterations in endometrial cancer by targeted next-generation sequencing. Exp Mol Pathol. 2016;100:8–12.CrossRefGoogle Scholar
  8. 8.
    Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505:495–501.CrossRefGoogle Scholar
  9. 9.
    Network CGA. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.CrossRefGoogle Scholar
  10. 10.
    Effenberger KA, Urabe VK, Prichard BE, Ghosh AK, Jurica MS. Interchangeable SF3B1 inhibitors interfere with pre-mRNA splicing at multiple stages. RNA. 2016;22:350–9.CrossRefGoogle Scholar
  11. 11.
    Paolella BR, Gibson WJ, Urbanski LM, Alberta JA, Zack TI, Bandopadhayay P, et al. Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability. Elife. 2017;6:e23268.CrossRefGoogle Scholar
  12. 12.
    Mortera-Blanco T, Dimitriou M, Woll PS, Karimi M, Elvarsdottir E, Conte S, et al. SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells. Blood. 2017;130:881–90.CrossRefGoogle Scholar
  13. 13.
    Zhang L, Zhou Y, Cheng C, Cui H, Cheng L, Kong P, et al. Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma. Am J Hum Genet. 2015;96:597–611.CrossRefGoogle Scholar
  14. 14.
    Gökmen-Polar Y, Neelamraju Y, Goswami CP, Gu X, Nallamothu G, Janga SC, et al. Expression levels of SF3B3 correlate with prognosis and endocrine resistance in estrogen receptor-positive breast cancer. Mod Pathol. 2015;28:677–85.CrossRefGoogle Scholar
  15. 15.
    Guo S, Yang J, Wu M, Xiao G. Clinical value screening, prognostic significance and key pathway identification of miR-204-5p in endometrial carcinoma: A study based on the Cancer Genome Atlas (TCGA), and bioinformatics analysis. Pathol Res Pract. 2019;215:1003–111.CrossRefGoogle Scholar
  16. 16.
    Hwang HM, Heo CK, Lee HJ, Kwak SS, Lim WH, Yoo JS, et al. Identification of anti-SF3B1 autoantibody as a diagnostic marker in patients with hepatocellular carcinoma. J Transl Med. 2018;16:177.CrossRefGoogle Scholar
  17. 17.
    Ohashi R, Schraml P, Batavia A, Angori S, Simmler P, Rupp N, et al. Allele loss and reduced expression of CYCLOPS genes is a characteristic feature of chromophobe renal cell carcinoma. Transl Oncol. 2019;12:1131–7.CrossRefGoogle Scholar
  18. 18.
    Neelamraju Y, Gonzalez-Perez A, Bhat-Nakshatri P, Nakshatri H, Janga SC. Mutational landscape of RNA-binding proteins in human cancers. RNA Biol. 2018;15:115–29.CrossRefGoogle Scholar
  19. 19.
    Dalton WB, Helmenstine E, Walsh N, Gondek LP, Kelkar DS, Read A, et al. Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation. J Clin Invest. 2019;130:4708–23.CrossRefGoogle Scholar
  20. 20.
    Samanta D, Semenza GL. Serine synthesis helps hypoxic cancer stem cells regulate redox. Cancer Res. 2016;76:6458–62.CrossRefGoogle Scholar
  21. 21.
    Zhang X, Bai W. Repression of phosphoglycerate dehydrogenase sensitizes triple-negative breast cancer to doxorubicin. Cancer Chemother Pharmacol. 2016;78:655–9.CrossRefGoogle Scholar
  22. 22.
    DeBoever C, Ghia EM, Shepard PJ, Rassenti L, Barrett CL, Jepsen K, et al. Transcriptome sequencing reveals potential mechanism of cryptic 3' splice site selection in SF3B1-mutated cancers. PLoS Comput Biol. 2015;11:e1004105.CrossRefGoogle Scholar
  23. 23.
    Alsafadi S, Houy A, Battistella A, Popova T, Wassef M, Henry E. Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage. Nat Commun. 2016;7:10615.CrossRefGoogle Scholar
  24. 24.
    Wu G, Fan L, Edmonson MN, Shaw T, Boggs K, Easton J, et al. Inhibition of SF3B1 by molecules targeting the spliceosome results in massive aberrant exon skipping. RNA. 2018;24:1056–66.CrossRefGoogle Scholar
  25. 25.
    Yoshimoto R, Kaida D, Furuno M, Burroughs AM, Noma S, Suzuki H, et al. Global analysis of pre-mRNA subcellular localization following splicing inhibition by spliceostatin A. RNA. 2017;23:47–57.CrossRefGoogle Scholar
  26. 26.
    Sciarrillo R, Wojtuszkiewicz A, El Hassouni B, Funel N, Gandellini P, Lagerweij T, et al. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma. EBioMedicine. 2019;39:215–25.CrossRefGoogle Scholar
  27. 27.
    Iwata M, Ozawa Y, Uenaka T, Shimizu H, Niijima J, et al. E7107, a new 7-urethane derivative of pladienolide D, displays curative effect against several human tumor xenografts [abstract 2989]. Proc Am Assoc Cancer Res. 2004;45:691.Google Scholar
  28. 28.
    Eskens FA, Ramos FJ, Burger H, O'Brien JP, Piera A, Piera A, et al. Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors. Clin Cancer Res. 2013;19:6296–304.CrossRefGoogle Scholar
  29. 29.
    Desterro J, Bak-Gordon P, Carmo-Fonseca M. Targeting mRNA processing as an anticancer strategy. Nat Rev Drug Discov. 2019.  https://doi.org/10.1038/s41573-019-0042-3.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 2020

Authors and Affiliations

  1. 1.Department of PathologyShanxi Medical UniversityTaiyuanPeople’s Republic of China
  2. 2.Shanxi Key Laboratory of Carcinogenesis and Translational Research of Esophageal CancerShanxi Medical UniversityTaiyuanPeople’s Republic of China
  3. 3.Department of General SurgeryThe First Hospital of Shanxi Medical UniversityTaiyuanPeople’s Republic of China
  4. 4.Department of Forensic MedicineShanxi Medical UniversityTaiyuanPeople’s Republic of China
  5. 5.Department of PathologyThe First Hospital of Shanxi Medical UniversityTaiyuanPeople’s Republic of China

Personalised recommendations